Pharma BD Deal Intelligence

Teva Pharmaceutical Industries Ltd. / Samsung Bioepis Co., Ltd.

2026 · Licensing/Option · Pending

Samsung Bioepis and Teva entered a global license, development and commercialization agreement on October 1, 2026 covering up to six potential biosimilar candidates. Two programs are confirmed at signing: SB41, a biosimilar candidate referencing Fasenra (benralizumab), and SB44, a biosimilar candidate referencing Ilaris (canakinumab), with four additional candidates available under option. Samsung Bioepis is responsible for development, regulatory registration and manufacture, while Teva is responsible for commercialization across global markets including the United States, Europe and Canada, with an option to expand into further territories. Financial terms were not disclosed. The agreement expands a long-standing partnership that already produced the US commercialization of EPYSQLI (eculizumab-aagh) and OPUVIZ (aflibercept) in Canada.

This deal is too recent to grade. Critic Score and Outcome Score are assigned after the announcement-week coverage settles and, for Outcome, after the 5-year post-close assessment window opens — expected 2031 at the earliest for this deal, once/if it closes.

Key facts

Related deals

See the full interactive analysis, sources & comparables →

← Browse all deals  ·  How we score deals

More: 2026 deals  ·  Teva Pharmaceutical Industries Ltd. deals